SANTEN, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.santeninc.com
Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator
Phase 4
Completed
- Conditions
- Cataract
- Interventions
- Drug: 1.5% levofloxacin ophthalmic solutionDrug: 0.5% moxifloxacin hydrochloride ophthalmic solution
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2009-02-06
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT00630019
- Locations
- 🇺🇸
Bucci Laser Vision & Ambulatory Surgery Center, Wilkes-Barre, Pennsylvania, United States
Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
Phase 1
Completed
- Conditions
- Diabetic Macular EdemaDiabetic Retinopathy
- Interventions
- Drug: MS-R001 (rapamycin)
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2010-07-26
- Lead Sponsor
- Santen Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00401115
- Locations
- 🇺🇸
Retina Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Texas Retina Associates, Arlington, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath